Boston Scientific to Buy Intera Oncology

Boston Scientific announced its intention to acquire Intera Oncology, the developer of the Intera 3000 hepatic artery infusion (HAI) pump and the chemotherapy drug floxuridine, both approved by the FDA for treating liver tumors caused by metastatic colorectal cancer. The pump delivers targeted chemotherapy to liver tumors with minimal systemic side effects and is currently approved for unresectable colorectal liver metastases before and after resection. Intera is also conducting studies to explore the pump’s use as a first-line, second-line, and adjuvant therapy for liver cancer. This acquisition aligns with Boston Scientific's strategy to broaden its interventional oncology offerings and address growing demand for innovative liver cancer treatments.

​

The acquisition is expected to close in the first half of 2025, pending regulatory conditions, though Boston Scientific anticipates a short-term dilutive impact on its 2025 earnings due to acquisition-related expenses. The deal follows Boston Scientific’s other major acquisitions this year, including Axonics and Silk Road Medical, highlighting its commitment to expanding in high-growth medical device markets. According to Peter Pattison, president of interventional oncology and embolization at Boston Scientific, the move is intended to enhance the company’s ability to treat liver cancer comprehensively while improving patient outcomes and minimizing side effects.